Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): Positioning statement from the Spanish Association of Urology

Autor:	J.M. Malet, J.L. Artiles, J. Caffaratti, M. Unda, A. Elizalde, Jose Luis Alvarez-Ossorio, Javier C. Angulo, J.M. Cózar, E. Miguélez, N. Cruz, M. de Cabo, Alfredo Rodríguez-Antolín, Emilio Martín Gutiérrez, G. Server, E. Lledó, M. Esteban, J. Mateos, M. Ozonas, M. Jiménez-Cidre, E. Solsona, Lourenzo Fernández Prieto, J. Mata, Alicia Gomez, C. Hernández, J.I. del Valle, C. Reina, M. Arrabal, J. Extramiana, Humberto Villavicencio, L.M. Nalda
Rok vydání:	2013
Předmět:	medicine.medical_specialty medicine.anatomical_structure Antiangiogenic agents business.industry Prostate Statement (logic) Urology medicine Cancer General Medicine medicine.disease business
Zdroj:	Actas Urológicas Españolas (English Edition). 37:321-323
ISSN:	2173-5786
DOI:	10.1016/j.acuroe.2013.04.001
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a3ef9ca870995f89680727f0162af089 https://doi.org/10.1016/j.acuroe.2013.04.001 Zobrazit plný text záznamu Full Text from ScienceDirect